Delving into the Latest Updates on Autologous gamma delta T cell therapy (TC BioPharm) with Synapse

Overview

Basic Info

Drug Type

T-lymphocyte cell therapy

Synonyms

Autologous d T Lymphocytes, Autologous g T Lymphocytes, Autologous T Lymphocytes

+ [2]

Target-

Mechanism

Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases+ [3]

Active Indication-

Inactive Indication

Advanced cancerKidney NeoplasmsLiver Cancer+ [4]

Originator Organization

TC BioPharm Ltd.

Active Organization-

Inactive Organization

TC BioPharm Ltd.M Group Holdings Ltd.

Drug Highest PhaseDiscontinuedPhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Safety and Efficacy of Ex-vivo Expanded Allogeneic γδ T-lymphocytes (OmnImmune®) in Patients With Active Relapsed or Refractory Acute Myeloid Leukaemia (AML) Who Are Not Eligible for or do Not Consent to High Dose Salvage Chemotherapy and/or Allogeneic Haematopoietic Cell Transplantation (HCT). A Dose Escalation, Open-label, Phase I Study

This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.

Start Date27 Nov 2018

Sponsor / Collaborator

TC BioPharm Ltd.

NCT02459067

/ TerminatedPhase 2

Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.

Start Date01 Dec 2015

Sponsor / Collaborator

TC BioPharm Ltd.

JPRN-UMIN000006128

/ CompletedPhase 2IIT

Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment. - Zoledronate-expanded autologous gamma/delta T cell therapy for NSCLC

Start Date01 Jul 2012

Sponsor / Collaborator

The University of Tokyo Hospital

100 Clinical Results associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

100 Translational Medicine associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

100 Patents (Medical) associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

100 Deals associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Neoplasms	Phase 3	GB	TC BioPharm Ltd.	-
Melanoma	Phase 3	GB	TC BioPharm Ltd.	-
Non-Small Cell Lung Cancer	Phase 3	GB	TC BioPharm Ltd.	-
Advanced cancer	Phase 2	GB	TC BioPharm Ltd.	01 Dec 2015
Renal Cell Carcinoma	Phase 2	GB	TC BioPharm Ltd.	01 Dec 2015
Refractory acute myeloid leukemia	Phase 1	CZ	TC BioPharm Ltd.	27 Nov 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2009	Not Applicable	Lymphoma	-	Autologous Cytotoxic T Lymphocytes (LMP2 CTLs)	gpuxnsiqzf(cupsxbayju) = sgrjyaausx lvpsfkcqjz (udpfdyqnen ) View more	-	01 Feb 2009
				Autologous Cytotoxic T Lymphocytes (LMP1/2 CTLs)	zphlwdhuqo(bhxgjrkcmc) = gvxxhwyani reeqwdawld (icgfqsliim )